32 Chapter 1 37. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7(1): 38. 38. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344(15): 1125-31. 39. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356(19): 1944-56. 40. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009; 20(4): 449-57. 41. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124(7): 1626-36. 42. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 20092010. JAMA 2012; 307(7): 693-703. 43. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 Suppl 5: F12-23. 44. Bernard HU. Regulatory elements in the viral genome. Virology 2013; 445(1-2): 197204. 45. Schwartz S. Papillomavirus transcripts and posttranscriptional regulation. Virology 2013; 445(1-2): 187-96. 46. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al. Mechanisms of human papillomavirusinduced oncogenesis. J Virol 2004; 78(21): 11451-60. 47. Richards RM, Lowy DR, Schiller JT, Day PM. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 2006; 103(5): 1522-7. 48. Day PM, Schiller JT. The role of furin in papillomavirus infection. Future Microbiol 2009; 4(10): 1255-62. 49. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 Suppl 5: F55-70. 50. Doorbar J. The E4 protein; structure, function and patterns of expression. Virology 2013; 445(1-2): 80-98. 51. Griffin H, Soneji Y, Van Baars R, Arora R, Jenkins D, van de Sandt M, et al. Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM. Mod Pathol 2015; 28(7): 97793. 52. 52. van Baars R, Griffin H, Wu Z, Soneji YJ, van de Sandt M, Arora R, et al. Investigating Diagnostic Problems of CIN1 and CIN2 Associated With High-risk HPV by Combining the Novel Molecular Biomarker PanHPVE4 With P16INK4a. Am J Surg Pathol 2015; 39(11): 1518-28. 53. Zummeren MV, Kremer WW, Leeman A, Bleeker MCG, Jenkins D, Sandt MV, et al. HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions. Mod Pathol 2018; 31(12): 1842-50. 54. Griffin H, Wu Z, Marnane R, Dewar V, Molijn A, Quint W, et al. E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. PLoS One 2012; 7(12): e49974. 55. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical
RkJQdWJsaXNoZXIy MjY0ODMw